Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Defence Therapeutics Inc (CSE:DTC)

0.8600 +0.0500 (+6.17%)
Streaming Delayed Price Updated: 1:59 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Defence Therapeutics Inc

Precision Medicine Helps Conquer Advanced-Stage Cancer
As North America reports a dramatic rise in advanced-stage cancer cases, experts are saying that major breakthroughs in oncology could make “now the best time in human history to get cancer.” According... 
Via PressReach
Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
(November 14, 2023) - Defence Therapeutics Inc. (CSE:DTC) (OTC Pink:DTCFF) (FSE:DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in 
Via PressReach
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
(November 7, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing cutting-edge 
Via PressReach
Topics Intellectual Property
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer
(October 18, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the 
Via PressReach
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to... 
Via PressReach
Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology
Leading pharmaceutical companies are diving headfirst into oncology, sparking a buzz in the cancer treatment world. Bristol Myers Squibb is the latest company to join the movement, announcing its plan... 
Via PressReach
Defence’s Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma
(October 17, 2023) - Defence Therapeutics Inc. (CSE:DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology 
Via PressReach
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant... 
Via PressReach
Big Pharma’s Billion-Dollar Bets on Advanced Cancer Therapies
Big Pharma is continuing its oncology buying spree, with a flurry of multi-billion-dollar deals, partnerships, and investments creating a buzz in the cancer treatment space. American pharmaceutical... 
Via PressReach
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
(October 10, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a biotechnology company developing various products for the 
Via PressReach
Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
(September 25, 2023) - Defence Therapeutics Inc. (CSE:DTC) (FSE:DTC) (OTC Pink:DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the 
Via PressReach
BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment
Vancouver, British Columbia--(Newsfile Corp. - May 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) - Defence Therapeutics... 
Via Newsfile
BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2023) - On FOX Business News broadcast on Sunday, May 7 at 5:30... 
Via Newsfile
Topics Supply Chain
BTV Features: Defence Therapeutics, Volatus Aerospace, NGEx Minerals, York Harbour Metals, & AuTECO Minerals
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2022) - On national TV Sat. November 12 & Sun. November 13, 2022... 
Via Newsfile
Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"... 
Via Newsfile
Topics Death Intellectual Property
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"... 
Via Newsfile
Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"... 
Via Newsfile
The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a biotechnology... 
Via Newsfile
Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased... 
Via Newsfile
Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased... 
Via Newsfile
Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company") is pleased... 
Via Newsfile
RETRANSMISSION: Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a pre-clinical... 
Via Newsfile
Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a pre-clinical... 
Via Newsfile
Defence Therapeutics AccuVAC-D001 Cancer Vaccine Generates Effective Long-lasting Anti-Tumoral Response
Vancouver, British Columbia--(Newsfile Corp. - May 25, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased... 
Via Newsfile
Defence Therapeutics, Strong Therapeutics Pipeline: ADC's, Cancer and COVID Vaccines
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian... 
Via Newsfile
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.